




RealRate

# REAL ESTATE 2015

HH Biotechnology Holdings CO  
Rank 37 of 58



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of HH Biotechnology Holdings CO are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of HH Biotechnology Holdings CO compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 18% points. The greatest weakness of HH Biotechnology Holdings CO is the variable Liabilities, Current, reducing the Economic Capital Ratio by 39% points.

The company's Economic Capital Ratio, given in the ranking table, is 45%, being 27% points below the market average of 72%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Cost of Revenue	5,056	Real Estate Investments, Net	0
Depreciation and Amortization	24	Liabilities	34,848
General and Administrative Expense	4,405	Assets	53,984
Goodwill and Intangible Assets	0	Revenues	5,822
Lease Income	5,822	Expenses	10,761
Liabilities, Current	34,848	Stockholders Equity	19,137
Liabilities, Long-term	0	Net Income	-4,313
Other Assets	53,984	Comprehensive Net Income	-4,594
Other Compr. Net Income	-562	ECR before Limited Liability	17%
Other Expenses	1,276	Economic Capital Ratio	45%
Other Liabilities	0		
Other Net Income	625		
Other Real Estate Investments, Net	0		
Other Revenues	0		
Real Estate Investment Property, Accumulated Depreciation	0		
Real Estate Investment Property, at Cost	0		